Search Results
Jul 06, 2026, 07:30 ET Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership
Amwell. This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives.
More news about: DarioHealth Corp.
Jun 30, 2026, 14:16 ET Academy Sports + Outdoors Launches Summer 250 Shop Featuring Patriotic Gear for Summer Celebrations
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced the launch of its Summer 250 Patriotic Gear shopping destination,
More news about: Academy Sports + Outdoors
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
Biotech's service portfolio includes:Nucleic Acid Synthesis and Modification Platform: Customized development of siRNA, ASO, and other modified oligonucleotides, including 2'-OMe, 2'-F, phosphorothioate (PS), and GalNAc conjugation technologies.Small Nucleic Acid
More news about: Tsingke Biotech
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
Biotech's service portfolio includes:Nucleic Acid Synthesis and Modification Platform: Customized development of siRNA, ASO, and other modified oligonucleotides, including 2'-OMe, 2'-F, phosphorothioate (PS), and GalNAc conjugation technologies.Small Nucleic Acid
More news about: Tsingke Biotech
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its
More news about: Pomerantz LLP
Jun 25, 2026, 08:30 ET Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
Phase Ib/II first-in-human study to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of its antisense oligonucleotide (ASO) molecule in children with KCNT1-related developmental and epileptic encephalopathy (KCNT1-DEE).
More news about: Servier Pharmaceuticals
Jun 23, 2026, 14:05 ET Academy Sports + Outdoors Continues Partnership with Boys & Girls Clubs of America to Broaden its Positive Impact
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced the extension of its national partnership with
More news about: Academy Sports + Outdoors
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its
More news about: Pomerantz LLP
Jun 16, 2026, 07:30 ET SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis
splicing mutation.About SpliSenseSpliSense is a clinical-stage biotechnology company developing ASO-based therapies for pulmonary diseases. The Company's proprietary inhaled ASO platform is designed to address the root causes of severe pulmonary disorders through modulation of gene expression
More news about: SpliSense
Jun 11, 2026, 14:05 ET Academy Sports + Outdoors Celebrates Father's Day With "Dadmas" Campaign Focused on Fun, Family, and Legendary Value
Nasdaq: ASO) is celebrating Father's Day with the launch of its "Dadmas" campaign, a seasonal initiative that reimagines Father's Day. Inspired by the excitement
More news about: Academy Sports + Outdoors
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its
More news about: Pomerantz LLP
Jun 10, 2026, 10:01 ET Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
Zorevunersen is an investigational therapy being developed for the treatment of Dravet syndrome. It is a proprietary antisense oligonucleotide (ASO) with the potential to become the first disease-modifying treatment aimed at addressing the underlying genetic cause of the disorder. The therapy works
More news about: DelveInsight Business Research, LLP
Jun 10, 2026, 09:15 ET TriNet's HR Plus Offering Surpasses 40,000 Users and Expands HR Support Capabilities for SMBs
comprehensive human resources solutions for small and medium-size businesses (SMBs), today announced that its Administrative Services Organization (ASO) solution offering, HR Plus, has surpassed 40,000 users, marking a key milestone since its launch last year.
More news about: TriNet
Jun 10, 2026, 05:00 ET Servier et n-Lorem Foundation s'unissent pour faire progresser la recherche dans les maladies neurodéveloppementales rares
Ce partenariat associera la technologie de pointe en oligonucléotides antisens (ASO) de n-Lorem et l'expertise en R&D de Servier, dans le but de faire progresser la technologie ASO et de proposer des approches de médecine de précision aux patients dans le monde entier.Servier
More news about: Servier
Jun 10, 2026, 04:00 ET Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world.Servier strengthens its
More news about: Servier
Jun 10, 2026, 04:00 ET Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world.Servier strengthens its
More news about: Servier
Jun 05, 2026, 09:05 ET Academy Sports + Outdoors Announces Quarterly Cash Dividend
Academy Sports and Outdoors, Inc. (the "Company" or "Academy") (Nasdaq: ASO) announced today that on June 4, 2026, its Board of Directors declared a quarterly cash dividend of $0.15 per share of the Company's common stock with
More news about: Academy Sports + Outdoors
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its
More news about: Pomerantz LLP
Jun 03, 2026, 12:23 ET Vensure Employer Solutions Launches Communication Hub, a Unified AI-Powered Employee Communication Platform
without adding administrative complexity. PrismHR, a Vensure Employer Solutions company and a leading technology platform serving the PEO, HCM and ASO service provider market, will offer
More news about: Vensure Employer Solutions
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its
More news about: Pomerantz LLP
May 28, 2026, 08:00 ET Summus Strengthens Executive Team With Appointment of Mike Tilton as Chief Commercial Officer
Operations, Group Sales, Finance, and Underwriting, delivering over $2 billion in revenue while significantly improving administrative services only (ASO) profitability. He also served as a Board Member and Advisor to Consortium Health Plans, helping integrate best practices and enable National Account
More news about: Summus
May 26, 2026, 08:55 ET Academy Sports + Outdoors Announces First Quarter Fiscal 2026 Results Conference Call
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to release its first quarter fiscal 2026 financial results before the market
More news about: Academy Sports + Outdoors
May 21, 2026, 18:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
press release announcing "topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease." Although Biogen described the results as "compelling," the study missed its primary
More news about: Pomerantz LLP
May 21, 2026, 05:31 ET Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight
Pharmaceuticals announced the first dose in the first in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an Antisense Oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing CMT2S.In March 2025, Actio Biosciences announced that the
More news about: DelveInsight Business Research, LLP
May 19, 2026, 09:04 ET Academy Sports + Outdoors to Open Three New Stores in Q2
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is excited to announce it will open three new locations this quarter. The first
More news about: Academy Sports + Outdoors